IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 143.99

Change

-1.92 (-1.32)%

Market Cap

USD 7.45B

Volume

1.38M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-1.04 (-1.10%)

USD 0.72B
BBH VanEck Biotech ETF

-2.24 (-1.26%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca..

-0.52 (-1.15%)

USD 0.19B
PTH Invesco DWA Healthcare Momentu..

-0.51 (-1.08%)

USD 0.15B
GNOM Global X Genomics & Biotechnol..

-0.21 (-1.87%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.34 (-1.18%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.26 (-1.68%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

-0.04 (0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.67% 38% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.67% 38% F 10% F
Trailing 12 Months  
Capital Gain -58.63% 25% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.63% 25% F 11% F
Trailing 5 Years  
Capital Gain -54.57% 25% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.57% 25% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 2.41% 38% F 47% F
Dividend Return 2.64% 38% F 44% F
Total Return 0.23% 50% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.60% 63% D 75% C
Risk Adjusted Return 12.82% 50% F 47% F
Market Capitalization 7.45B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.